PHOENIX, Ariz. — Sept. 30, 2010 — DNA methylation — a modification of DNA linked to gene regulation — is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).
And at specific points of DNA, "global hypomethylation," in which many genes lose the modification, may be associated with the step-by-step development of myeloma, according to a scientific paper published this month in the journal Cancer Research.
"This is the first study to show that hypomethylation occurs early in the development of multiple myeloma and increases through disease progression," said Dr. Bodour Salhia, a TGen cancer researcher and the paper's lead author.
DNA methylation suppresses the expression of viral genes and other harmful elements incorporated over time into an individual's genome. In cancer, hypermethylation at certain genomic locations can turn tumor suppressing genes off, while hypomethylation in some instances may lead to the over-expression of oncogenes, or those genes that give rise to cancer, and is linked to chromosomal instability.
However, there is still much to learn about the consequences of altered methylation.
In this study, researchers examined the methylation status of more than 1,500 CpGs. This is shorthand for C-phosphate-G, or cytosine and guanine — two of the four chemicals that comprise DNA — separated by a phosphate group, which links the two nucleosides together.
Researchers used a high-throughput universal bead array technology to examine CpG methylation at different stages of multiple myeloma, evaluating DNA methylation events associated with the progression of tumors.
They performed DNA methylation profiling analysis for more than 800 genes, including tumor suppressors, oncogenes, and genes involved in cancer-related cellular processes. This process contrasts with previous studies that focused on the analysis of a single gene.
They found only a few genes that were hypermethylated, but importantly found many more hypomethylated genes, even in the earliest stages of multiple myeloma.
"Our data suggest that the overall degree of methylation may have some prognostic value, and further studies are needed to determine the functional and clinical significance of our findings," said Dr. John Carpten, Director of TGen's Integrated Cancer Genomics Division and the paper's senior author.
Dr. Salhia, added, "This study represents the most comprehensive examination to date of the role of methylation in multiple myeloma, and is expected to lead to an improved understanding of the biological mechanisms involved in the development of this type of cancer."
The study of DNA methylation falls under epigenetics — an emerging field in cancer research. Unlike the study of genetics, epigenetics refers to the study of gene activity that does not involve hardwiring alterations in the genetic code. These epigenetic events, which lay atop the genome, are an intricate and heritable mechanism of regulating the expression of genes.
"Understanding the full spectrum of epigenetic modifications will be key to improving the clinical management of the disease, and studies should continue to find new ways of treating multiple myeloma by targeting the multiple myeloma epigenome. This study also emphasizes that hypomethylating strategies may not be the next necessary steps in drug development." said Rafael Fonseca, M.D., Deputy Director of Mayo Clinic Cancer Center in Arizona.
Tissue samples and research collaboration was provided by the Mayo Clinic in Arizona and the Multiple Myeloma Genomics Initiative, and the Multiple Myeloma Research Consortium.
The Multiple Myeloma Research Foundation and the Multiple Myeloma Research Consortium provided funding for the study.
Cancer Research is one of six peer-reviewed scientific journals published by the Philadelphia-based American Association for Cancer Research, founded in 1907, the world's oldest and largest scientific organization focused on high-quality, innovative cancer research.
About Mayo Clinic
Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,700 physicians, scientists and researchers, and 50,100 allied health staff work at Mayo Clinic, which has campuses in Rochester, Minn.; Jacksonville, Fla.; and Scottsdale/Phoenix, Ariz.; and community-based providers in more than 70 locations in southern Minnesota, western Wisconsin and northeast Iowa. These locations treat more than half a million people each year. Mayo Clinic Cancer Center is one of 40 U.S. medical centers that have been named as a National Cancer Institute (NCI) Comprehensive Cancer Center and the only national, multi-site center with the designation. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.
Mayo Clinic Public Affairs
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
TGen Senior Science Writer
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.